非アルコール性脂肪性肝炎(NASH)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0682
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:1034
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥810,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2020, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 53, 49, 1, 7, 164, 66 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Non-Alcoholic Steatohepatitis (NASH) – Overview
Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Development
Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Assessment
Non-Alcoholic Steatohepatitis (NASH) – Companies Involved in Therapeutics Development
Non-Alcoholic Steatohepatitis (NASH) – Drug Profiles
Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects
Non-Alcoholic Steatohepatitis (NASH) – Discontinued Products
Non-Alcoholic Steatohepatitis (NASH) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by 89bio Ltd, H1 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ABIONYX Pharma SA, H1 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Abivax SA, H1 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Acquist Therapeutics, H1 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd, H1 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Affinicon ApS, H1 2020

【掲載企業】

89bio Ltd
ABIONYX Pharma SA
Abivax SA
Acquist Therapeutics
AdAlta Ltd
Affinicon ApS
Afimmune Biopharma Ltd
Akero Therapeutics Inc
Albireo Pharma Inc
Aldeyra Therapeutics Inc
Algernon Pharmaceuticals Inc
Aligos Therapeutics Inc
Allergan Plc
Allysta Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Altavant Sciences Inc
Alteogen Inc
Altimmune Inc
Amgen Inc
Angion Biomedica Corp
AptaBio Therapeutics Inc
Aptamer Sciences Inc
AptamiR Therapeutics Inc
Araim Pharmaceuticals Inc
Arcturus Therapeutics Ltd
Arkay Therapeutics LLC
Arrowhead Pharmaceuticals Inc
ARTham Therapeutics Inc
Ascletis Inc
Asdera
Assembly Biosciences Inc
AstraZeneca Plc
Auransa Inc
Avaliv Therapeutics Inc
Axcella Health Inc
BBN Cardio Therapeutics
BerGenBio ASA
Betagenon AB
Bioio LLC
Bird Rock Bio Inc
Blade Therapeutics Inc
BLR Bio LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Buto Biopharma Inc
Cadila Healthcare Ltd
Califia Bio Inc
Can-Fite BioPharma Ltd
Carmot Therapeutics Inc
CellCure
Centaurus Therapeutics Inc
ChemoCentryx Inc
ChemomAb Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd.
China NT Pharma Group Co Ltd
Cirius Therapeutics Inc
CohBar Inc
Coherus BioSciences Inc
ConSynance Therapeutics Inc
Continuum Biosciences Inc
Corbus Pharmaceuticals Inc
Corcept Therapeutics Inc
Curadim Pharma Co Ltd
Cyclerion Therapeutics Inc
Cytodyn Inc
D&D Pharmatech Co Ltd
Daiichi Sankyo Co Ltd
Dicerna Pharmaceuticals Inc
Dr. Falk Pharma GmbH
DURECT Corp
Eli Lilly and Co
Enanta Pharmaceuticals Inc
EncuraGen Inc
Engitix Ltd
Enleofen Bio Pte Ltd
Enyo Pharma SA
Enzychem Lifesciences Corp
Epitracker Inc
Esperion Therapeutics Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Fochon Pharmaceutical Ltd
Forma Therapeutics Inc
Future Medicine Co Ltd
Galectin Therapeutics Inc
Galecto Biotech AB
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
Gencia LLC
General Regeneratives Shanghai Ltd
Genfit SA
GenKyoTex SA
GI Innovation Co Ltd
Gilead Sciences Inc
Gmax Biopharm Ltd
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
H. Lundbeck AS
Hana Pharm Co Ltd
Hanmi Pharmaceuticals Co Ltd
HemoShear Therapeutics LLC
Hepagene Therapeutics Shanghai Inc
Hepion Pharmaceuticals
Heprotech Inc
Hinova Pharmaceuticals Inc
HotSpot Therapeutics Inc
Imago Pharmaceuticals Inc
Immupharma Plc
Immuron Ltd
Indalo Therapeutics Inc
Inmune Bio Inc
Innovate Biopharmacueticals Inc
Innovimmune Biotherapeutics Inc
Inorbit Therapeutics AB
Integral Molecular Inc
Intercept Pharmaceuticals Inc
INVENT Pharmaceuticals Inc
InventisBio Inc
Inventiva
Ionis Pharmaceuticals Inc
J2H Biotech
Jecure Therapeutics Inc
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Joyce Biotech Corp
KinDex Pharmaceuticals Inc
Kinomedica Pty Ltd
Kirrhos Pharmaceuticals LLC
KoBioLabs Inc
Korea United Pharm Inc
Kowa Co Ltd
Krisani Bio Sciences Pvt Ltd
Kyorin Pharmaceutical Co Ltd
Laekna Therapeutics Shanghai Co Ltd
LG Chem Ltd
LifeMax Laboratories Inc
Liminal BioSciences Inc
Lin Bioscience Inc
Lipidio Pharmaceuticals Inc
Lipocine Inc
LISCure Biosciences Co Ltd
Lynkogen Inc
Macrophage Therapeutics Inc
Madrigal Pharmaceuticals Inc
Mallinckrodt Plc
Max Biopharma Inc
Melior Pharmaceuticals I Inc
Merck & Co Inc
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
MetiMedi Pharmaceuticals Co Ltd
Micelle BioPharma Inc
Mina Therapeutics Ltd
Mitotherapeutix LLC
Mitsubishi Tanabe Pharma Corp
Morphic Holding Inc
Mperia Therapeutics Inc
MYR GmbH
Naia Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanjing Transthera Biosciences Co Ltd
NeuroVive Pharmaceutical AB
Nexel Co Ltd
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
Nivarta Inc
NorthSea Therapeutics BV
Novartis AG
Novo Nordisk AS
NuSirt Biopharma Inc
Oasis Pharmaceuticals LLC
Oramed Pharmaceuticals Inc
Osteoneurogen Inc
Palo BioFarma SL
Pattern Therapeutics
PegBio Co Ltd
Pfizer Inc
pH Pharma Co Ltd
Pharmaxis Ltd
Phenex Pharmaceuticals AG
Pliant Therapeutics Inc
Poxel SA
Promethera Biosciences SA
Protalix BioTherapeutics Inc
Proterris Inc
PTC Therapeutics Inc
RadBio
Redx Pharma Plc
Regenasome Pty Ltd
Regulus Therapeutics Inc
reMYND NV
Revive Therapeutics Ltd
Rhamnopharma Inc
Sagimet Biosciences
Saje Pharma LLC
Salix Pharmaceuticals Ltd
Sanofi
ScandiCure AB
Sciwind Biosciences Co Ltd
Scohia Pharma Inc
Seal Rock Therapeutics Inc
Seres Therapeutics Inc
SFA Therapeutics LLC
Shanghai Anruite Biological Medicine Technology Co Ltd
Shenzhen HighTide Biopharmaceutical Ltd
Shionogi & Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Sinew Pharma Inc
Sirnaomics Inc
SparkBioPharma Inc
SteroTherapeutics LLC
Suzhou Zelgen Biopharmaceutical Co Ltd
Sveikatal Inc
Synlogic Inc
T3D Therapeutics Inc
TaiwanJ Pharmaceuticals Co Ltd
Terns Pharmaceuticals Inc
TES Pharma SRL
Theratechnologies Inc
Thetis Pharmaceuticals LLC
Tiziana Life Sciences Plc
TRACON Pharmaceuticals Inc
TreeFrog Therapeutics SAS
Valin Technologies Ltd
Vascular Biogenics Ltd
Vectus Biosystems Ltd
Venenum Biodesign LLC
Verlyx Pharma Inc
Vidasym Inc
Viking Therapeutics Inc
Visionary Pharmaceuticals Inc
Vivus Inc
Wave Life Sciences Ltd
Xenexus Pharmaceuticals Pty Ltd
XORTX Therapeutics Inc
YD Life Science Co
Yuhan Corp
Zafgen Inc
Zebra Discovery Ltd
Zhejiang Doer Biologics Corp
ZyVersa Therapeutics Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[非アルコール性脂肪性肝炎(NASH)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆